Surya Chundru1, Diego Martin1, Puneet Sharma1, Ryan Pathak2, Amanda Cox2, Lance W. Farr2, Tim James2, Peter Jezzard3
1University Medical Center, University of Arizona, Tucson, AZ, United States; 2Acuitas Medical, Swansea, United Kingdom; 3Department of Clinical Neurology, University of Oxford, Oxford
Non-invasive measurement of liver fibrosis in chronic liver disease (CLD) remains an unmet clinical need. We have developed a Fine Texture Analysis technique (wavelength analysis of fine texture wavelengths below the resolution limit of clinical MRI) and applied this technique to specially acquired MR data to evaluate the capacity for detecting liver fibrosis (LF). LF should alter the normal background liver texture to produce gradient stages of signature wavelength distributions as the coarser fibrotic texture replaces the finer vascular normal texture. Our results show good correlation between clinical assessment of disease stage and spectral features, supporting our hypothesis.